Show simple item record

dc.contributor.authorJoshi, LT
dc.date.accessioned2021-11-13T12:58:09Z
dc.date.issued2021-12-14
dc.identifier.issn2516-8290
dc.identifier.issn2516-8290
dc.identifier.other000298
dc.identifier.urihttp://hdl.handle.net/10026.1/18348
dc.description.abstract

In June 2021, I wrote a strongly worded opinion piece published in the New Statesman about the G7 Summit and antimicrobial resistance (AMR) [1]. The piece highlighted that AMR should be addressed in the G7 Summit agenda and that our world leaders must recognize that research and investment into feasible solutions are urgently needed. This personal view adds to that original article. The G7 Summit took place in Carbis Bay, Cornwall, UK on the 11–13 June 2021 and the UK took Presidency of the G7 group of nations [2]. The G7 comprises seven member countries, namely the UK, the USA, Canada, Japan, Germany, France and Italy, as well as the EU (a ‘non-enumerated member’). The summit represented over 60% of people living in the democratic world, i.e. over half the world’s economy [3]. In numbers, that is 2.2billion people being represented by 11 leaders making serious decisions around 1 table in Cornwall. The theme was Build Back Better. The main priority during the UK’s presidency is ‘leading the global recovery from coronavirus while strengthening our resilience against future pandemics’ [4].

dc.format.extent000298-
dc.format.mediumElectronic-eCollection
dc.languageen
dc.language.isoen
dc.publisherMicrobiology Society
dc.subjectCOVID-19
dc.subjectG7
dc.subjectantimicrobial resistance
dc.subjectclimate change
dc.subjectpandemic
dc.subjectpolicy
dc.titleThe G7 Summit 2021: Time for our world leaders to step up to the challenge of Anti-Microbial Resistance
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35024558
plymouth.issue12
plymouth.volume3
plymouth.publisher-urlhttp://dx.doi.org/10.1099/acmi.0.000298
plymouth.publication-statusPublished
plymouth.journalAccess Microbiology
dc.identifier.doi10.1099/acmi.0.000298
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2021-11-03
dc.rights.embargodate2021-12-18
dc.identifier.eissn2516-8290
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1099/acmi.0.000298
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-12-14
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV